Fitzsimon_menu

Innovation is happening. Right here.

Fitzsimons Innovation Community is a sprawling campus of leading-edge laboratory workspace where innovative health and life sciences companies of all sizes take their research to the next level to cure diseases, save lives, and improve care.

Smart, inclusive, forward-thinking, and highly educated people lead life sciences innovation in Colorado, the Hub for Health Impact. Together, we welcome life sciences organizations looking to call Colorado home and to collaborate with a robust community already in on the secret: the health and life sciences industry in Colorado is strong and making a global impact on the future of health.

 Move in, and build your vision here—today.

Community

The emphasis is on Community

We called it a community for a reason. From the board of directors to the newest company on campus, everyone at Fitzsimons Innovation Community knows that easy access to collaboration has direct results on success. From idea incubation to final-product manufacturing, your end-to-end innovation can come alive right here on our campus. All that Colorado sunshine is just a bonus.

Community

Cutting-edge discoveries in action

62%

Companies Hiring

Fitzsimons Innovation Community member companies are thriving. 62% of companies added employees to their workforce.

75%

Companies Fundraising

Most Fitzsimons Innovation Community member companies are actively involved in fundraising to power their progress.

16+

New Innovations

Fitzsimons Innovation Community member companies introduced more than 16 new innovations to the market in 2023.

$116M

Capital Raised

Last year, Fitzsimons Innovation Community member companies attracted more than $116M in investments to support R&D, prepare for clinical trials, accelerate commercialization, and retain or recruit talent.

75%

Companies with Discoveries

Fitzsimons Innovation Community member companies made news with major breakthrough discoveries last year. Areas included molecular biology, pharmaceuticals, medical device, research tools, cell and gene therapy, material science, and diagnostics.

50%

Companies Forging Strategic Partnerships

Fitzsimons Innovation Community member companies forged strategic partnerships for business collaboration, legal services, and venture capital opportunities.

*Fitzsimons Innovation Community Member Growth Survey responses (January – December 2023)

A heritage of healthcare and innovation

Fitzsimons Innovation Community stands on the grounds that once held the Fitzsimons Army Hospital, where soldiers returning from World War I were treated. The Colorado high altitude has always been a destination for advancements in lung treatment, and 100 years ago, soldiers sought cures for tuberculosis and mustard gas exposure right here.

After the Army decommissioned the hospital in the 1990s, ideas for the current University of Colorado Anschutz Medical Campus and Fitzsimons Innovation Community began to percolate. That rich history of discovery, care, and research continues to inspire our vision a century later.

Our team is on your team

You know best when it comes to your projects, and we know how to keep you up and running with first-class scientific facilities management and community engagement. Our priority is to help you thrive on this campus and we have the proven tools and expertise to make that happen.

Bruce Schmidt

Chief Engineer

Don Larson

Facilities engineer

Juliena Carlson

Property Administrator

Julie Ehler

Controller

Kelly Brough

President & CEO

Kenneth Ho

Chief Operating Officer

Laurie Troge

Chief of Staff

Lyle Artz

Site manager

Sue Niblo

Senior property manager

“The workspace has been perfect for our projects, but the most impressive thing to me has been the community. We’ve collaborated with researchers from the CU Anschutz Medical Campus, networked with other Fitzsimons Innovation Community members, and bounced ideas off some of the best minds in healthcare. And it’s all contributed to us moving forward in our research.”

Scott Deeter

CEO, InVitria

“I park my car in the morning, and then I never move it until I leave after work. We walk to lunch and meetings and take advantage of the outdoor space as much as we can during the day. Work-life balance happens right on campus.”

Kristin Nixon

President, PhosphoSolutions

Community

Fitzsimons Innovation Community News

Fitzsimons Innovation Community Names Kenneth Ho as Chief Operating Officer
News | Jul 14, 2025

Fitzsimons Innovation Community Names Kenneth Ho as Chief Operating Officer

Fitzsimons Innovation Community, a thriving hub where researchers, practitioners, educators, and innovators collaborate to bring life-changing healthcare solutions to patients, announced the appointment of Kenneth Ho as chief operating officer. A highly respected real estate developer with more than 25 years of experience, Ho will play a pivotal role in bringing the Community’s ambitious Master Plan to life.

Fitzsimons Innovation Community Appoints Real Estate Veteran as New COO
News | Jul 09, 2025

Fitzsimons Innovation Community Appoints Real Estate Veteran as New COO

A real estate developer with more than 25 years of experience has been appointed as the new chief operating officer of the Fitzsimons Innovation Community in Aurora. Kenneth Ho, the new COO, will play a pivotal role in bringing the community’s master plan to life. Ho has over two decades of experience in real estate development, investment and planning, with a specialization in complex, mixed-use communities.

Fitzsimons Innovation Community Names Kenneth Ho as Chief Operating Officer
News | Jul 08, 2025

Fitzsimons Innovation Community Names Kenneth Ho as Chief Operating Officer

Fitzsimons Innovation Community, a thriving hub where researchers, practitioners, educators, and innovators collaborate to bring life-changing healthcare solutions to patients, announces the appointment of Kenneth Ho as Chief Operating Officer. A highly respected real estate developer with more than 25 years of experience, Ho will play a pivotal role in bringing the Community’s ambitious Master Plan to life.

GelSana Selected for MedTech Innovator 2025 Cohort
News | Jul 07, 2025

GelSana Selected for MedTech Innovator 2025 Cohort

GelSana Therapeutics, Inc. has been selected to join the 2025 MedTech Innovator cohort, the world’s largest accelerator for medical device companies. GelSana is one of only 65 companies—representing the top 4% of nearly 1,500 global applicants—chosen for this year’s program. This recognition reflects the incredible work of our team and validates the potential of our solution to make a meaningful impact on healthcare.

Colorado Hub for Health Impact Builds Nationwide Momentum with 2025 Campaign to Attract Life Sciences Companies, Talent, and Investment
News | Jul 01, 2025

Colorado Hub for Health Impact Builds Nationwide Momentum with 2025 Campaign to Attract Life Sciences Companies, Talent, and Investment

Colorado Hub for Health Impact, the national economic development campaign positioning Colorado as an epicenter for health innovation, launches its 2025 campaign with new partner investment and a clear focus: attract life sciences companies, talent, and investors to a community that elevates science.

Aurora Clears Path for 7,266 Homes to Anchor Fitzsimons Life Sciences Hub
News | Jun 26, 2025

Aurora Clears Path for 7,266 Homes to Anchor Fitzsimons Life Sciences Hub

Aurora City Council has approved a massive increase in allowable housing at Fitzsimons Innovation Community, a move intended to transform the bioscience campus into a full-fledged neighborhood. Fitzsimons CEO Kelly Brough called the change “an obligation” to honor the site’s history while shaping a future that attracts talent and builds community.

Fitzsimons Campus Poised to Include Thousands of New Housing Units
News | Jun 26, 2025

Fitzsimons Campus Poised to Include Thousands of New Housing Units

A change to the Fitzsimons Innovation Community’s master plan in Aurora will allow eight times more residential units to be built on the medical campus.The Aurora City Council on Monday approved an amendment to the general development plan that increases the Fitzsimons Innovation Community residential unit cap from 850 units to 7,266 new units. Changes also include improvements to street, utility, drainage, parks and open space on site. Kelly Jean Brough, President and CEO of Fitzsimons Innovation Community, said the change will bring together the grander vision of a more interconnected campus.

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients
News | Jun 24, 2025

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

The University of Colorado Cancer Center this year celebrates its 40th anniversary, highlighting significant advances in research and innovations that include new therapies, treatments and insights into cancer prevention. One of the leaders in cell-based immune therapies is CU Cancer Center member Terry Fry, M.D., executive director of the Gates Institute, a translational research institute on the CU Anschutz Medical Campus that produces CAR T and other cellular therapies for research. Gates recently launched a clinical trial of a CAR for pediatric patients with relapsed or refractory pre B-cell acute lymphoblastic leukemia (B-ALL).

Gene-Edited Stem Cells Aim to Reverse Rheumatoid Arthritis
News | Jun 06, 2025

Gene-Edited Stem Cells Aim to Reverse Rheumatoid Arthritis

A new approach for gene editing will get its shot in a common and chronic autoimmune disorder. Rheumatoid arthritis is an autoimmune disease that causes pain and swelling in the joints. It affects about one percent of the adult population. With its HLA gene editing approach, RheumaGen believes it can create a one-time cure for rheumatoid arthritis that solves for uncontrolled disease and ineffective therapies.

RheumaGen Betting on HLA Gene Editing to Tackle Autoimmune Disorders
News | May 30, 2025

RheumaGen Betting on HLA Gene Editing to Tackle Autoimmune Disorders

A startup is developing a new class of treatments for autoimmune diseases leveraging an approach to editing genes in the HLA family, which play a critical role in the immune system. RheumaGen, which spun out from the University of Colorado Anschutz Medical Campus, launched earlier this year with $15 million in Series A funding co-led by investment firms SPRIM Global Investments and William Taylor Nominees. The company focuses on autoimmune conditions with genetic risk factors linked with certain variants in HLA genes.

Want to stay on top of what’s happening on campus?

Sign up for regular updates from Fitzsimons Innovation Community.